Novartis India Limited primarily trades in drugs and pharmaceuticals. More Details
Flawless balance sheet unattractive dividend payer.
Share Price & News
How has Novartis India's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 500672 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 500672 underperformed the Indian Pharmaceuticals industry which returned 48.4% over the past year.
Return vs Market: 500672 underperformed the Indian Market which returned 2.8% over the past year.
Price Volatility Vs. Market
How volatile is Novartis India's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Novartis India undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 500672 (₹634.8) is trading above our estimate of fair value (₹77.42)
Significantly Below Fair Value: 500672 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 500672 is poor value based on its PE Ratio (114.5x) compared to the IN Pharmaceuticals industry average (22.8x).
PE vs Market: 500672 is poor value based on its PE Ratio (114.5x) compared to the Indian market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 500672's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 500672's PB Ratio (2.2x) is in line with the IN Pharmaceuticals industry average.
How is Novartis India forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Novartis India has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Novartis India's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Novartis India competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Novartis India performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 500672 has high quality earnings.
Growing Profit Margin: 500672's current net profit margins (3.2%) are lower than last year (9.2%).
Past Earnings Growth Analysis
Earnings Trend: 500672's earnings have declined by 27.5% per year over the past 5 years.
Accelerating Growth: 500672's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 500672 had negative earnings growth (-67.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).
Return on Equity
High ROE: 500672's Return on Equity (1.9%) is considered low.
How is Novartis India's financial position?
Financial Position Analysis
Short Term Liabilities: 500672's short term assets (₹8.1B) exceed its short term liabilities (₹2.3B).
Long Term Liabilities: 500672's short term assets (₹8.1B) exceed its long term liabilities (₹1.2B).
Debt to Equity History and Analysis
Debt Level: 500672 is debt free.
Reducing Debt: 500672 had no debt 5 years ago.
Debt Coverage: 500672 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 500672 has no debt, therefore coverage of interest payments is not a concern.
What is Novartis India current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 500672's dividend (1.58%) is higher than the bottom 25% of dividend payers in the Indian market (0.55%).
High Dividend: 500672's dividend (1.58%) is low compared to the top 25% of dividend payers in the Indian market (2.28%).
Stability and Growth of Payments
Stable Dividend: 500672's dividends per share have been stable in the past 10 years.
Growing Dividend: 500672's dividend payments have not increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (180.4%), 500672's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sanjay Murdeshwar (54 yo)
Mr. Sanjay Prabhakar Murdeshwar serves as Vice Chairman and Managing Director at Novartis India Limited since June 15, 2019. Mr. Murdeshwar served as Managing Director of AstraZeneca Pharma India Limited s ...
CEO Compensation Analysis
Compensation vs Market: Sanjay's total compensation ($USD122.79K) is below average for companies of similar size in the Indian market ($USD316.55K).
Compensation vs Earnings: Insufficient data to compare Sanjay's compensation with company performance.
|MD & Vice Chairman||1.33yrs||₹9.06m||no data|
|Chief Financial Officer||1.33yrs||₹15.00m||no data|
|Company Secretary & Compliance Officer||3.67yrs||₹8.40m||no data|
|Chief Executive Officer of Novartis||2.67yrs||no data||no data|
Experienced Management: 500672's management team is considered experienced (2 years average tenure).
|MD & Vice Chairman||1.33yrs||₹9.06m||no data|
|Honorary Chairman of Novartis AG||no data||no data||no data|
|Non-Executive Non-Independent Director||4.33yrs||₹13.90m||no data|
|Independent Director||14.75yrs||₹1.00m||no data|
|Independent Non-Executive Director||0.33yr||no data||no data|
|Non-Executive Chairman||12.17yrs||no data||no data|
|Independent Non-Executive Director||4.5yrs||₹1.00m||no data|
Experienced Board: 500672's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Novartis India Limited's company bio, employee growth, exchange listings and data sources
- Name: Novartis India Limited
- Ticker: 500672
- Exchange: BSE
- Founded: 1947
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹15.674b
- Shares outstanding: 24.69m
- Website: https://www.novartis.in
Number of Employees
- Novartis India Limited
- Inspire BKC, G Block
- Part of 601 and 701
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|500672||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Apr 1999|
|NOVARTIND||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||Apr 1999|
Novartis India Limited primarily trades in drugs and pharmaceuticals. The company offers pharmaceutical products in the areas of bone and pain, calcium portfolio, gynecology, and neurosciences. It also pro ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/25 12:32|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.